Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Key findings from animal studies Superior body weight reduction compared to GLP-1 monoagonists in diet-induced obese rodent models Significant reduction in hepatic fat content in NASH models, suggesting relevance for metabolic liver disease research Improvements in lipid profiles (triglycerides, LDL cholesterol) beyond what was observed with GLP-1 monoagonism alone Evidence of increased energy expenditure supporting the glucagon receptor-mediated thermogenesis hypothesis Clinical Research Timeline (Updated Through 2026) Retatrutide has now progressed through Phase 3 clinical trials with three major readouts between December 2025 and May 2026, representing the most advanced clinical development of any triple hormone receptor agonist to date
A nuut shake with chia or flax is an easy fibre fix that loves your gut and your glow
Loud noise can disrupt the flow in blood vessels that supply oxygen to hair cells, depriving these cells of nutrients needed to function and leading to cell damage through a process known as ischemia
Alberti, K
